http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 16:46:34 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Longeveron+%28LGVN%29+Misses+Q2+EPS+by+1c/26913776.html <p>Longeveron (NASDAQ: LGVN) reported Q2 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $326 thousand.</p><p>For earnings history and earnings-related data on Longeveron (LGVN) <a href="http://www.streetinsider.com/ec_earnings.php?q=LGVN">click here</a>.</p> http://www.streetinsider.com/Earnings/Longeveron+%28LGVN%29+Misses+Q2+EPS+by+1c/26913776.html Wed, 12 Aug 2026 16:46:34 -0400 LGVN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+12/26913011.html si-local-file:///var/storage/secattach/20260812/26913011.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+12/26913011.html Wed, 12 Aug 2026 16:14:00 -0400 LGVN O.49866458 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+12/26913011.html si-local-file:///var/storage/secattach/20260812/26913011.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Longeveron+Inc.+++++++++++For%3A+Aug+12/26913011.html Wed, 12 Aug 2026 16:14:00 -0400 LGVN O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Press+Releases/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458 http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html <ul><li><em>On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication</em></li><li><em>Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE Healthspan competition based on published clinical trial results which indicated laromestrocel increased 6-minute walk distance in patients with aging frailty</em></li><li><em>Three new independent Directors join Longeveron’s Board of Directors</em></li><li><em>Company to host conference call and webcast today at 4:30 p.m. ET<br/><br/></em></li></ul> <p align="justify">MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=a41aB3xpN9df3VqyO3I_1OatpA1jHmuIk7jejF9xa2NFWTLhmx3xVj53K0RqZ-cgw3hgW7eJt9VUxWSb0WdWU9GR8oodvcifaK5HFscSYfw=" rel="nofollow" target="_blank">Longeveron http://www.streetinsider.com/Globe+Newswire/Longeveron+Announces+2026+Second+Quarter+Financial+Results+and+Provides+Business+Update/26912723.html Wed, 12 Aug 2026 16:05:00 -0400 A.06822034 A.10670324 A.19655944 A.31066700 A.50216920 LGVN LGVNR O.03307993 O.20026344 O.20738343 O.22422661 O.31410200 O.49866458